Why Yahoo!, Idenix Pharmaceuticals, and Progenix Pharmaceuticals Tumbled Today

The broader stock market posted big losses again today, and bad news hit several individual stocks hard. Find out why Yahoo! fell almost 9%, Idenix Pharmaceuticals dropped 10%, and Progenix Pharmaceuticals plunged 27% today.

Jan 29, 2014 at 8:31PM

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

After a one-day respite, the stock market fell sharply again today, as the Federal Reserve chose not to change its glide-path toward curbing its bond buying under its quantitative easing program. Yet the roughly 1% drop in major market benchmarks paled in comparison to larger drops in Yahoo! (NASDAQ:YHOO), Idenix Pharmaceuticals (NASDAQ:IDIX), and Progenix Pharmaceuticals (NASDAQ:PGNX).

Yahoo! fell almost 9% despite reporting impressive revenue and earnings results that came in much higher than investors had expected, as well as favorable revenue guidance for the current quarter. But shareholders weren't pleased about the extent to which Yahoo!'s digital-ad share has dropped in recent years, and with earnings guidance suggesting that profit margins could narrow substantially, the bullish story for the Internet-portal giant took a bit of a hit today. Moreover, results tied to Chinese Internet player Alibaba, in which Yahoo! holds a 24% stake, suggested slowing growth there as well. The stock's earnings multiple is high enough that even small declines in future growth expectations can have a big impact on the share price if investors lose confidence in the trajectory of its revenue and net income.

Idenix dropped 10%, giving up a substantial portion of the 17% gains it posted yesterday. The biopharmaceutical company said on Tuesday that it would sell 16.42 million shares of stock to private-equity firm Baupost Group for $6.50 per share, helping Idenix raise more than $100 million in funding. Even though Baupost got a bargain price for the shares, paying more than 5% less than its closing value on Monday, investors still celebrated the vote of confidence on Tuesday. Even after today's drop, the shares fetch 11% more than Baupost paid, giving the company a nice immediate paper profit.

Progenix plunged 27% after results of its experimental PSMA-ADC treatment for prostate cancer reportedly included deaths of two patients in a phase 2 trial. In advance of comments that Progenix said it would make tomorrow concerning the study, investors had little choice but to speculate on the possible toxicity of the treatment and weigh it against its potential upside. With doubts about whether Progenix will move forward with a phase 3 trial of the treatment, investors are worried that a promising candidate could disappear from the company's pipeline.

Don't get impatient with your best stocks
Day-to-day drops shouldn't make you lose confidence in your portfolio, as long as your investment strategy involves buying shares in solid businesses and keeping them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.

Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool recommends Yahoo! Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers